Table 2:
Demographic and laboratory features of patients with compensated cirrhosis due to virus C infection without HCC according to their AFP serum level.
| Parameter | AFP <15 ng/ml (N=1446) | AFP ≥ 15 ng/ml (N=622) | p-value |
|---|---|---|---|
| Age* | 60 (25, 82) | 66 (33, 82) | <0.001 |
| Male Sex | 719/1446 (49%) | 299/622 (48) | 0.055 |
| Severe necroinflammatory activity** | 798/1446 (55.2%) | 414/622 (66.6%) | <0.001 |
| Severe NASH** | 593/1446 (41%) | 421/622 (67.8%) | <0.001 |
| Severe Steatosis** | 902/1446 (62.4%) | 498/622 (80.1%) | <0.001 |
| Platelets (x103)* | 143 (12, 1752) | 113 (33, 650) | <0.001 |
| AST* | 69 (20, 338) | 97 (21, 431) | <0.001 |
| ALT* | 82 (9, 604) | 103 (11, 526) | <0.001 |
| Blood glucose* | 105 (60, 367) | 106 (69, 454) | 0.07 |
| INR* | 1.1 (0.7, 3.4) | 1.1 (0.3, 2.9) | 0.7 |
| Creatinine* | 0.8 (0.3, 4.3) | 0.8 (0.3, 2.2) | 0.1 |
| Total Bilirubin* | 0.86 (0.1, 3.47) | 0.97 (0.2, 3.2) | <0.001 |
| HCV RNA (x103) (IU/ml)* | 886 (0.231, 27,795) | 908 (0.24, 22,800) | 0.795 |
* (median, range)
** estimated through FibroMax™ (Biopredictive, Paris, France)